Ranibizumab and Long-Term Diabetic Macular Edema OutcomesRanibizumab and Long-Term Diabetic Macular Edema Outcomes
The benefits of individualized ranibizumab treatment for diabetic macular edema (DME) persist for at least three years, according to results from the RESTORE extension study. Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news
More News: Diabetes | Endocrinology | Health | Lucentis | Opthalmology | Ranibizumab Injection | Study